Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover

Clovis Oncology, Inc. CLVS incurred adjusted loss of $1.88 per share in the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of $1.68 and the year-ago loss of $1.27 per share.